Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow INCY by emailGet an email when INCY pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about INCY, unsubscribe in one click. Privacy
📣 What INCY Says Is Next
early 2029 · “Topline data from the VIVID-6 study are anticipated in early 2029.”
Company press release, Jul 28, 2026 · SEC filing
second half of 2026 · “Data from the Phase 1 cohort evaluating INCA033989 as a monotherapy and in combination with ruxolitinib in treatment naïve MF patients are anticipated in the second half of 2026.”
Company press release, Jul 28, 2026 · SEC filing
second half of 2026 · “Topline data from the Phase 2 trial evaluating axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic GVHD are anticipated in the second half of 2026.”
Company press release, Jul 28, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full INCY picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for INCY and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.